Skip to main content

What is Basal-Bolus Therapy?

Important Safety Information

Double click to edit

  1. Jones RE, Huether SE Chapter 20: Alterations of hormonal regulation. Pathophysiology The Biologic Basis for Disease in Adults & Children. Ed: McCance KL, Huether SE. Mosby, Inc. St. Louis, Missouri: 2002.
  2. American Diabetes Association. Visiting your healthcare team. Accessed: July 11, 2013.
  3. American Diabetes Association. Common terms. Accessed: July 11, 2013.
  4. Types of insulin. University of California-San Francisco Diabetes Education. Accessed: July 11, 2013.
  5. Global Guideline for Type 2 Diabetes. International Diabetes Federation. Accessed: July 11, 2013.
  6. Rodbard HW, Blonde L, Braithwaite SS, et al. AACE diabetes mellitus guidelines, Encocr Pract. 2007;13(suppl 1);3-68.
  7. Standards of Medical Care in Diabetes. Position Statement. American Diabetes Association. Diabetes Care. 2012;35(suppl 1):S11-S63.


The content in the shaded area has been supplied by Novo Nordisk and access is restricted to health care professionals only. Novo Nordisk has no control over, and accepts no responsibility or liability for, any other content featured here and gives no representation or warrantly (express or implied) as to the information contained in such content. Further, Novo Nordisk does not recommend or endorse any third party's products or services that may be referred to.

NovoLog® (insulin aspart injection) 100 U/mL Indications and Usage

NovoLog® (insulin aspart injection) 100 U/mL is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. 

Important Safety Information


  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. 
  • Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. 
  • To avoid medication errors and accidental mix-ups between NovoLog® and other insulin products, instruct patients to always check the insulin label before injection. 
  • Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog®
  • As with all insulins, NovoLog® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death.  Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered. 
  • Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. 

NovoLog® continuous subcutaneous infusion route (insulin pump): Do not mix NovoLog® with any other insulin or diluent. 

Adverse Reactions

  • Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. 

Use in Specific Populations

  • NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age. 
  • Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment. These patients may require more frequent blood glucose monitoring and dose adjustments. 

Please click here for Prescribing Information.